NM_032043.3:c.3079G>A
Variant summary
Our verdict is Likely benign. The variant received -4 ACMG points: 0P and 4B. BP4_Strong
The NM_032043.3(BRIP1):c.3079G>A(p.Glu1027Lys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000136 in 1,614,190 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 17/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. E1027A) has been classified as Likely benign.
Frequency
Consequence
NM_032043.3 missense
Scores
Clinical Significance
Conservation
Publications
- familial ovarian cancerInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- Fanconi anemiaInheritance: AR Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, Illumina
- Fanconi anemia complementation group JInheritance: AR Classification: DEFINITIVE, STRONG Submitted by: G2P, ClinGen, Ambry Genetics, Labcorp Genetics (formerly Invitae)
- hereditary breast carcinomaInheritance: AD Classification: STRONG, LIMITED, NO_KNOWN Submitted by: ClinGen, Genomics England PanelApp, Ambry Genetics, Labcorp Genetics (formerly Invitae)
- colorectal adenomaInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -4 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| BRIP1 | NM_032043.3 | c.3079G>A | p.Glu1027Lys | missense_variant | Exon 20 of 20 | ENST00000259008.7 | NP_114432.2 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| BRIP1 | ENST00000259008.7 | c.3079G>A | p.Glu1027Lys | missense_variant | Exon 20 of 20 | 1 | NM_032043.3 | ENSP00000259008.2 |
Frequencies
GnomAD3 genomes AF: 0.0000723 AC: 11AN: 152202Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000278 AC: 7AN: 251446 AF XY: 0.0000221 show subpopulations
GnomAD4 exome AF: 0.00000752 AC: 11AN: 1461870Hom.: 0 Cov.: 34 AF XY: 0.00000963 AC XY: 7AN XY: 727234 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000722 AC: 11AN: 152320Hom.: 0 Cov.: 32 AF XY: 0.0000671 AC XY: 5AN XY: 74480 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
not provided Uncertain:2
In silico analysis supports that this missense variant does not alter protein structure/function; Observed in individuals with suspected hereditary breast and ovarian cancer or colorectal cancer and/or polyps (PMID: 25980754, 27978560, 28528518); This variant is associated with the following publications: (PMID: 25980754, 27978560, 28528518, 31658756, 11301010)
Familial cancer of breast;C1836860:Fanconi anemia complementation group J Uncertain:1Benign:1
Hereditary cancer-predisposing syndrome Uncertain:1Benign:1
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
not specified Uncertain:1
DNA sequence analysis of the BRIP1 gene demonstrated a sequence change, c.3079G>A, in exon 20 that results in an amino acid change, p.Glu1027Lys. This sequence change has been described in three individuals with colorectal cancer, or breast/ovarian cancer, or suspected Lynch syndrome-related cancer/polyps (PMIDs: 27978560, 25980754, 28528518). This sequence change has been described in the gnomAD database with a low frequency of 0.028% in the African/African American subpopulation (dbSNP rs371185409). The p.Glu1027Lys change affects a poorly conserved amino acid residue of the BRIP1 protein. The p.Glu1027Lys substitution appears to be benign using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). Due to these contrasting evidences and the lack of functional studies, the clinical significance of the p.Glu1027Lys change remains unknown at this time.
BRIP1-related disorder Uncertain:1
The BRIP1 c.3079G>A variant is predicted to result in the amino acid substitution p.Glu1027Lys. This variant has been reported in individuals undergoing testing of Lynch syndrome, colorectal cancer or hereditary breast/ovarian cancer (Supplemental Table 2, Yurgelun MB et al 2015. PubMed ID: 25980754; eTable3, Pearlman et al 2017. PubMed ID: 27978560; Cock-Rada AM et al 2018. PubMed ID: 28528518). This variant is reported in 0.028% of alleles in individuals of African descent in gnomAD and has conflicting interpretations regarding its pathogenicity in ClinVar, ranging from likely benign to uncertain (https://www.ncbi.nlm.nih.gov/clinvar/variation/230429/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence.
Fanconi anemia complementation group J Uncertain:1
The BRIP1 c.3079G>A p.(Glu1027Lys) missense change has a maximum subpopulation frequency of 0.03% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). The in silico tool REVEL predicts a benign effect on protein function, but to our knowledge this prediction has not been confirmed by functional studies. To our knowledge, this variant has not been reported as pathogenic in individuals with BRIP1-associated conditions. In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance.
Familial cancer of breast Uncertain:1
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at